Joel Isaacson & Co’s ImmunityBio IBRX Stock Holding History

Joel Isaacson & Co’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$219K	Hold	25,000	–	–	0.01%	446
2026 Q1	$192K	Buy	+25,000	New	+$171K	0.01%	433

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Joel Isaacson & Co's IBRX Position: Q2 2026 in Review

Joel Isaacson & Co held its ImmunityBio (IBRX) position steady in Q2 2026 at 25,000 shares worth $219K. The position accounts for 0.01% of the portfolio, ranked #446.

Joel Isaacson & Co first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Joel Isaacson & Co held 25,000 shares of ImmunityBio worth $219K as of Q2 2026.
Joel Isaacson & Co left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up 0.01% of Joel Isaacson & Co's portfolio in Q2 2026, its #446 holding.
Joel Isaacson & Co first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Joel Isaacson & Co's 13F filing for Q2 2026, filed 4 Aug 2026.